
What smart money is saying about Aroa Biosurgery
1 fund in our archive has pitched Aroa Biosurgery — most recently Forager Funds in December 2025.
Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. The company's products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
Fund coverage · 1 thesis
- Forager FundsDecember 2025
Aroa Biosurgery is a regenerative tissue company with high-margin partner sales and accelerating direct distribution that is driving operating leverage and cash generation.
Read the full thesis
Read every full thesis on Aroa Biosurgery
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→